Search

Your search keyword '"Pellacani, G."' showing total 2,078 results
Start Over Author "Pellacani, G."

Refine your results

2,078 results on '"Pellacani, G."'

226. Dermoscopic diagnosis of amelanotic/hypomelanotic melanoma

Author

Pizzichetta MA, Kittler H, Stanganelli I, Ghigliotti G, Corradin MT, Rubegni P, Cavicchini S, De Giorgi V, Bono R, Alaibac M, Astorino S, Ayala F, Quaglino P, Pellacani G, Argenziano G, Guardoli D, Specchio F, Serraino D, Talamini R, Italian Melanoma Intergroup (IMI), Pizzichetta, Ma, Kittler, H, Stanganelli, I, Ghigliotti, G, Corradin, Mt, Rubegni, P, Cavicchini, S, De Giorgi, V, Bono, R, Alaibac, M, Astorino, S, Ayala, F, Quaglino, P, Pellacani, G, Argenziano, G, Guardoli, D, Specchio, F, Serraino, D, Talamini, R, Italian Melanoma Intergroup, (IMI), Pizzichetta, M. A, Corradin, M. T, Argenziano, Giuseppe, and Talamini, R.

Subjects
Seborrheic keratosis, Pathology, medicine.medical_specialty, Skin Neoplasms, Dermoscopy, Dermatology, Case-Control Studie, Humans, Melanoma, Amelanotic, Retrospective Studies, Amelanotic Melanoma, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Germline mutation, medicine, Nevus, Amelanotic melanoma, neoplasms, Melanoma, Hypopigmentation, business.industry, medicine.disease, Microphthalmia-associated transcription factor, Amelanotic, Superficial spreading melanoma, Case-Control Studies, 030220 oncology & carcinogenesis, medicine.symptom, business
Abstract

Amelanotic/hypomelanotic melanoma (AHM) is a subtype including melanomas with little or no melanin pigmentation, amelanotic melanoma (AM); it represents 2-8 % of all melanomas.(1-2) AM may be difficult to diagnose because of lack of pigmentation and symmetry: recently, germline mutations have been reported in the MC1R gene and to a certain extent also in the MITF gene.(3) (This article is protected by copyright. All rights reserved.)

Published
2017

228. Quantification of soil erosion using 7Be in a steep watershed used for natural grazing in Brazil.

Author

Esquivel, Alexander Dario, Moreira, Rubens Martins, Monteiro, Roberto Pellacani G., Rochido Dos Santos, Anômora Ariadne, Valladares, Diego Leonardo, and Juri Ayub, Jimena

Subjects
SOIL erosion, SOIL profiles, WATERSHEDS, GRAZING, SOIL sampling
Abstract

Cosmogenic 7Be was used to evaluate soil loss in a mountainous micro-watershed near Belo Horizonte, Southwest Brazil. Two nearby sites were selected, a reference site in a flat area and an eroded site in a hill slope. At the reference site, soil samples were collected monthly throughout the year in order to evaluate seasonal variations of 7Be inventory in soil and its relation with the precipitation regime. Additionally, rainwater was collected and the expected 7Be soil content was predicted. At the reference site, the 7Be inventory shows seasonal variations, in accordance with the rainy season, and its distribution in the soil profile shows an exponential decrease in depth (h0 = 6.9 ± 0.6 kg m–2; r2 = 0.97). At the eroded site, two soil sampling campaigns were performed in order to measure soil erosion in the watershed. The estimated net erosion was 42.2 ± 3.7 t ha–1, indicating the loss of upper 5mm of soil per year. This corresponds to soil losses in the area in the range from moderate to severe erosion. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

229. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis. SUPREME study

Author

Costanzo, A., Bianchi, L., Flori, M. L., Malara, G., Stingeni, L., Bartezaghi, M., Carraro, L., Castellino, G., Bottoni, U, Brazzelli, V, Burlando, M, Cantoresi, F, Capo, A, Cattaneo, A, Cusano, F, Dapavo, P, Del Giglio, M, Di Lernia, V, Di Nuzzo, S, Dusi, D, Fargnoli, Mc, Franchi, C, Galluzzo, M, Ghilardi, A, Hansel, K, Loconsole, F, Lora, V, Malagoli, P, Mastrandrea, V, Megna, M, Mercuri, Sr, Letizia Musumeci, M, Naldi, L, Narcisi, A, Offidani, A, Pagnanelli, G, Papini, M, Patrizi, A, Pau, M, Pellacani, G, Peris, K, Persechino, S, Piaserico, S, Pietroleonardo, L, Prignano, F, Reseghetti, A, Romanelli, M, Russo, F, Sirna, R, Skroza, N, Stinco, G, Trevisini, S, Zane, C, Zichichi, L, Zini, A., Costanzo, A., Bianchi, L., Flori, M. L., Malara, G., Stingeni, L., Bartezaghi, M., Carraro, L., Castellino, G., Persechino, Severino, Pau, Monica, Cusano, Francesco, Russo, Filomena, Stinco, Giuseppe, Ghilardi, Alberto, Del Giglio, Micol, De Luca, Giuseppe, Brazzelli, Valeria, Fargnoli, Maria Concetta, Capo, Alessandra, Mastrandrea, Valentina, Piaserico, Stefano, Franchi, Chiara, Zane, Cristina, Cattaneo, Angelo, Galluzzo, Marco, La Selva, Roberta, Di Nuzzo, Sergio, Megna, Matteo, Pellacani, Giovanni, Peris, Ketty, Patrizi, Annalisa, Trevisini, Sara, Pagnanelli, Gianluca, Skroza, Nevena, Malagoli, Piergiorgio, Resghetti, Alberto, Burlando, Martina, Loconsole, Francesco, Offidani, Anna Maria, Albertini, Giuseppe, Mercuri, Santo Raffaele, Bottoni, Ugo, Dusi, Daniele, Zini, Antonio, Pietroleonardo, Lucia, Cantoresi, Franca, Sirna, Riccardo, Lora, Viviana, Hansel, Katharina, Prignano, Francesca, and Natalini, Ylenia

Subjects
Adult, Male, medicine.medical_specialty, Psoriasis, secukinumab, Genotyping Techniques, Dermatology, HLA-C Antigens, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Antibodies, 030207 dermatology & venereal diseases, 03 medical and health sciences, Antibodies, Monoclonal, Biomarkers, Female, Genetic Predisposition to Disease, Humans, Interleukin-17, Italy, Middle Aged, Prospective Studies, Psoriasis, Treatment Outcome, 0302 clinical medicine, Internal medicine, Severity of illness, Monoclonal, medicine, Clinical endpoint, Adverse effect, Prospective cohort study, Humanized, Settore MED/35 - Malattie Cutanee e Veneree, business.industry, medicine.disease, Confidence interval, 030220 oncology & carcinogenesis, Secukinumab, Interleukin 17, business
Abstract

Background Understanding genetic variations is important in predicting treatment response and forms the basis for identifying new pharmacogenetic and pharmacogenomic targets for psoriasis treatment. There are limited data on the efficacy of secukinumab in relation to genetic markers. Objectives To evaluate the efficacy and safety of secukinumab 300 mg in HLA-Cw6-positive (Cw6-POS) and HLA-Cw6-negative (Cw6-NEG) patients with moderate-to-severe chronic plaque-type psoriasis. Methods SUPREME was a 24-week, phase IIIb study with an extension period up to 72 weeks. Primary end point was Psoriasis Area Severity Index (PASI) 90 response rate after 16 weeks. Results In total, 434 patients were recruited: 185 (42·6%) were Cw6-POS and 246 (56·7%) were Cw6-NEG (three not assessed). Mean ± SD age was 45·2 ± 13·2 years (Cw6-POS 42·7 ± 13·1; Cw6-NEG 47·2 ± 12·9). The baseline PASI score was comparable between the cohorts [Cw6-POS 20·7 ± 8·99; Cw6-NEG 21·5 ± 9·99 (P = 0·777)]. At week 16, PASI 90 was achieved in 80·4% of Cw6-POS and 79·7% of Cw6-NEG patients (difference 0·76; 95% confidence interval -7·04 to 8·23). No differences in absolute PASI at week 16 (Cw6-POS 1·36 ± 3·58; Cw6-NEG 1·18 ± 2·29) were observed. The overall safety profile of secukinumab was consistent with that previously reported. No statistically significant difference was detected in the rate of treatment-emergent adverse events [Cw6-POS 42·7%; Cw6-NEG 49·6% (P = 0·295)]. A high PASI 90 response was achieved with secukinumab with a fast reduction in absolute PASI. Conclusions Determination of HLA-Cw6 status for secukinumab therapy is unnecessary, as it is highly effective regardless of HLA-Cw6 status.

Published
2018

238. Standardization of dermoscopic terminology and basic dermoscopic parameters to evaluate in general dermatology (non‐neoplastic dermatoses): an expert consensus on behalf of the International Dermoscopy Society

Author

Errichetti, E., primary, Zalaudek, I., additional, Kittler, H., additional, Apalla, Z., additional, Argenziano, G., additional, Bakos, R., additional, Blum, A., additional, Braun, R.P., additional, Ioannides, D., additional, Lacarrubba, F., additional, Lazaridou, E., additional, Longo, C., additional, Micali, G., additional, Moscarella, E., additional, Paoli, J., additional, Papageorgiou, C., additional, Russo, T., additional, Scope, A., additional, Stinco, G., additional, Thomas, L., additional, Toncic, R.J., additional, Tschandl, P., additional, Cabo, H., additional, Hallpern, A., additional, Hofmann‐Wellenhof, R., additional, Malvehy, J., additional, Marghoob, A., additional, Menzies, S., additional, Pellacani, G., additional, Puig, S., additional, Rabinovitz, H., additional, Rudnicka, L., additional, Vakirlis, E., additional, Soyer, P., additional, Stolz, W., additional, Tanaka, M., additional, and Lallas, A., additional

Published
2019
Full Text
View/download PDF

240. The integration of dermoscopy and reflectance confocal microscopy improves the diagnosis of lentigo maligna

Author

Cinotti, E., primary, Fiorani, D., additional, Labeille, B., additional, Gonzalez, S., additional, Debarbieux, S., additional, Agozzino, M., additional, Ardigò, M., additional, Lacarrubba, F., additional, Farnetani, F., additional, Carrera, C., additional, Cevenini, G., additional, Le Duff, F., additional, Tognetti, L., additional, Pellacani, G., additional, Rubegni, P., additional, and Perrot, J.L., additional

Published
2019
Full Text
View/download PDF

241. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience

Author

Conti, A., primary, Peccerillo, F., additional, Amerio, P., additional, Balato, A., additional, Bardazzi, F., additional, Bianchi, L., additional, Burlando, M., additional, Cannavò, S.P., additional, Chiricozzi, A., additional, Dapavo, P., additional, De Simone, C., additional, Fargnoli, M.C., additional, Gambardella, A., additional, Gisondi, P., additional, Malagoli, P., additional, Malara, G., additional, Mugheddu, C., additional, Offidani, A.M., additional, Piaserico, S., additional, Prignano, F., additional, Stingeni, L., additional, and Pellacani, G., additional

Published
2019
Full Text
View/download PDF

249. Real-time high resolution diagnostic imaging for prostatic tissue with ex vivo fluorescence confocal microscopy: Our preliminary experience

Author

Puliatti, S., primary, Bertoni, L., additional, Pirola, G.M., additional, Azzoni, P., additional, Bevilacqua, L., additional, Eissa, A., additional, Elsherbiny, A., additional, Sighinolfi, M.C., additional, Chester, J., additional, Rocco, B.M.C., additional, Micali, S., additional, Bagni, I., additional, Reggiani Bonetti, L., additional, Maiorana, A., additional, Malvehy, J., additional, Longo, C., additional, Montironi, R., additional, Patel, V., additional, Pellacani, G., additional, and Bianchi, G., additional

Published
2019
Full Text
View/download PDF

250. Ex vivo fluorescence confocal microscopy in the assessment of urothelial carcinoma grading in bladder and ureter: Our preliminary experience

Author

Puliatti, S., primary, Eissa, A., additional, Bevilacqua, L., additional, Pellacani, G., additional, Sighinolfi, M.C., additional, Azzoni, P., additional, Bertoni, L., additional, Reggiani Bonetti, L., additional, Elsherbiny, A., additional, Micali, S., additional, Patel, V., additional, Rocco, B.M.C., additional, and Bianchi, G., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results